Pharmaceutical Executive
May 02, 2015
Features
34
4
Expert panel on rare disease highlights the challenges of serving expectant patients in this uniquely complex market access environment.
April 22, 2015
From the Editor
34
4
Learnings gleaned from our annual EAB meeting, hosted this year by Dr. David Nash, Dean of the Thomas Jefferson University School of Population Health.
April 21, 2015
Features
34
4
Although the strategic hurdles of biosimilars market entry are not new, the task of imitating substantially more complex molecular entities offers up a host of new operational questions for pharma.
April 16, 2015
Features
34
4
Pharm Exec profiles the journey of Healthcare Businesswomen’s Association 2015 Woman of the Year, Denice Torres, whose career demonstrates that doing right starts with finding-and being-yourself.
April 16, 2015
Features
34
4
The looming shift to cross-border compliance in Europe puts the spotlight on the evolving role of chief compliance officers.
April 14, 2015
Columns
34
4
Is it time to view cell therapy companies differently on Wall Street-even distinct from biotech?
April 13, 2015
Columns
34
4
Making sense of the new cost-containment model and value-for-money conundrums like those in the HCV space.
April 12, 2015
Columns
34
4
FDA is under pressure to moderate oversight of pharma advertising and promotion.
April 08, 2015
Features
34
4
Although the strategic hurdles of biosimilars market entry are not new, the task of imitating substantially more complex molecular entities offers up a host of new operational questions for pharma.
April 01, 2015
Columns
34
4
The EU’s proposed new study on off-label prescribing is just another way of kicking the subject into the long grass.
April 01, 2015
Columns
34
4
Does patient choice matter to antitrust enforcers?
April 01, 2015
Special Sponsored Section
34
4
Energy reform may be stealing the headlines in Mexico, but a rising regulatory authority, the beginnings of healthcare reform, and cost-competitive manufacturing are fueling future growth in the country’s pharma industry-for domestic and global players alike.